Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

ECM-binding properties of extracellular vesicles: advanced delivery strategies for therapeutic applications in bone and joint diseases

Wang P., Husch JFA., Arntz OJ., van der Kraan PM., van de Loo FAJ., van den Beucken JJJP.

Narrative Review on Cartilage Damage, Immune Modulation, published in Cell Commun Signal (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Cell Commun Signal (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40176023
PMCID
PMC11967064
DOI
10.1186/s12964-025-02156-5
Citations
14

Abstract (original English)

Extracellular vesicles (EVs) and the extracellular matrix (ECM) are essential in maintaining bone and joint health by facilitating intercellular communication, regulating tissue processes and providing structural support. EVs with a large surface area carry diverse biomolecules to steer the function of cells in their surroundings. To understand how EVs localize to specific sites, we here review the available knowledge on EV surface biomolecules and their interactions with ECM components that are crucial for regulating bone remodeling, cartilage maintenance, and immune responses, playing roles in both tissue homeostasis and pathological conditions, such as arthritis and osteoporosis. More importantly, using analyses of animal experimental data, we illustrate the effect of ECM-based biomaterials (e.g. hydrogels, decellularized matrices, and ECM-mimetic scaffolds) as carriers for EVs toward effective EV delivery in regenerative and immunomodulatory therapies in bone and joint tissue. These biomaterials enable sustained release and targeted delivery of EVs, promoting bone and cartilage regeneration. The insights of this review can be utilized to advance the development of cutting-edge therapies for skeletal tissue regeneration and disease management.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Bone and BonesExtracellular MatrixAnimalsHumansBone DiseasesJoint DiseasesBiocompatible MaterialsDrug Delivery SystemsExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research